The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial.

doi:10.1016/j.clinthera.2018.07.019

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial.

Clinical therapeutics - 1 Sept 2018

Lawitz Eric, Bidair Mohamed, Marbury Thomas, Jones Christopher T, Barve Avantika, Magnusson Baldur, Barkan David T, Bodendorf Ursula, Bracken Kathryn, Canino Erica, Chen Darlene, Dabovic Kristina, Heimbach Tycho, Ison Marjorie, Jones Catherine L, Kovacs Steven J, Lakshman Jay P, Li Bin, Raman Prakash, Steiner-Swiat Rachael, Thohan Sanjeev, Wong Kelly A, Zhong Weidong, Colvin Richard A

Abstract excerpt

PURPOSE: Infection with hepatitis C virus is the leading cause of infectious disease mortality in the United States. BZF961 is a novel small molecule inhibitor of the hepatitis C virus NS3-4A protease. Here we present the results of a randomized, double-blinded, placebo-controlled, multicentered study in treatment-naïve patients with chronic hepatitis C virus genotype-1 infection. METHODS: Patients were enrolled...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Organic Chemicals

Share to Ritonavir

Share to Viral Load

Share to Viral Nonstructural Proteins

Source

Open in PubMed

Identifiers

PMID: 30185394
DOI: 10.1016/j.clinthera.2018.07.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial.PMID 30185394Read ↗

Exploratory study of oral combination antiviral therapy for hepatitis C.Semantic proximity Read ↗

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.Semantic proximity Read ↗

Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

New antiviral agents for the treatment of hepatitis C: ABT-450.Semantic proximity Read ↗

Pharmacology Update for the Treatment of Hepatitis C Virus.Semantic proximity Read ↗

A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.Semantic proximity Read ↗

Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.Semantic proximity Read ↗

Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.Semantic proximity Read ↗

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.Semantic proximity Read ↗

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.Semantic proximity Read ↗

Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.